Hepatitis a virus antibody in chronic diffuse liver disease

Area of Science:

• Hepatology
• Virology
• Epidemiology

Background:

• Hepatitis A virus (HAV) infection is a global health concern.
• Understanding the prevalence of HAV antibodies (anti-HAV) is crucial for public health strategies.
• The role of HAV in chronic liver disease requires further investigation.

Purpose of the Study:

• To determine the prevalence of anti-HAV in different patient groups and healthy controls in Hungary.
• To assess the association between HAV infection and chronic diffuse liver disease.
• To evaluate the age-specific prevalence of HAV infection.

Main Methods:

• Radioimmunoassay using a HAVAB (Abbott)-kit was employed.
• Study included 175 patients with chronic diffuse liver disease, 67 patients with cardiovascular/metabolic diseases, and 118 healthy adults.
• Prevalence of anti-HAV was analyzed across age groups and disease categories.

Main Results:

• A very high prevalence of anti-HAV was observed in all study groups in Hungary.
• Over 98% of individuals over 40 tested positive for anti-HAV.
• The majority of HAV infections were asymptomatic, with less than 11.4% reporting a history of acute hepatitis.
• Anti-HAV prevalence increased with age, reaching 100% in older populations.

Conclusions:

• Hepatitis A virus infection is highly endemic in Hungary, particularly in adults over 40.
• HAV infection appears to be largely asymptomatic in the studied population.
• The findings do not support a causal link between hepatitis A virus infection and the development of chronic diffuse liver disease.